PURPOSE: Paclitaxel is an effective therapy for patients with solid tumors. While the albumin-bound formulation eliminates the hypersensitivity reaction caused by the Cremaphor solvent, significant peripheral neuropathy persists when given over the standard 30-min infusion time. We sought to determine if the incidence and severity of peripheral neuropathy could be reduced when the infusion time is lengthened to 2-h. METHODS: This was an open-label, single-arm, phase 2 study of albumin-bound paclitaxel given over 2 h. Twenty-five patients with advanced non-small-cell lung cancer were enrolled to determine whether the longer infusion reduced the severity of neuropathy compared to data from an earlier cohort of 40 similar patients treated over 30 min Patients received 125 mg/m(2) of albumin-bound paclitaxel IV over 2 h without premedication on days 1, 8, and 15 of a 28-day cycle. Radiologic assessment was performed every 8 weeks. RESULTS: There was a significant 0.45 grade decrease in average peripheral neuropathy experienced by patients in the 2-h group versus the 30-min group (90% CI, 0.03-0.87). There was, in addition, a significant decrease in grade ≥2 peripheral neuropathy in patients treated over 2 h versus 30 min (28% vs. 55%, 2-sided P = 0.04). A decrease in grade ≥2 neutropenia (20% vs. 48%, 2-sided P = 0.07) was also observed. The median survival, 11 months, was the same for both groups. CONCLUSION: Increasing the infusion time of albumin-bound paclitaxel from 30 min to 2 h resulted in a significant reduction in both average and grade ≥2 peripheral neuropathy without affecting survival.
PURPOSE:Paclitaxel is an effective therapy for patients with solid tumors. While the albumin-bound formulation eliminates the hypersensitivity reaction caused by the Cremaphor solvent, significant peripheral neuropathy persists when given over the standard 30-min infusion time. We sought to determine if the incidence and severity of peripheral neuropathy could be reduced when the infusion time is lengthened to 2-h. METHODS: This was an open-label, single-arm, phase 2 study of albumin-bound paclitaxel given over 2 h. Twenty-five patients with advanced non-small-cell lung cancer were enrolled to determine whether the longer infusion reduced the severity of neuropathy compared to data from an earlier cohort of 40 similar patients treated over 30 min Patients received 125 mg/m(2) of albumin-bound paclitaxel IV over 2 h without premedication on days 1, 8, and 15 of a 28-day cycle. Radiologic assessment was performed every 8 weeks. RESULTS: There was a significant 0.45 grade decrease in average peripheral neuropathy experienced by patients in the 2-h group versus the 30-min group (90% CI, 0.03-0.87). There was, in addition, a significant decrease in grade ≥2 peripheral neuropathy in patients treated over 2 h versus 30 min (28% vs. 55%, 2-sided P = 0.04). A decrease in grade ≥2 neutropenia (20% vs. 48%, 2-sided P = 0.07) was also observed. The median survival, 11 months, was the same for both groups. CONCLUSION: Increasing the infusion time of albumin-bound paclitaxel from 30 min to 2 h resulted in a significant reduction in both average and grade ≥2 peripheral neuropathy without affecting survival.
Authors: Mark A Socinski; Georgiy M Manikhas; Daniil L Stroyakovsky; Anatoly N Makhson; Sergey V Cheporov; Sergei V Orlov; Petr K Yablonsky; Paul Bhar; Jose Iglesias Journal: J Thorac Oncol Date: 2010-06 Impact factor: 15.609
Authors: Nuhad K Ibrahim; Brian Samuels; Ray Page; Dinesh Doval; Kirtikumar M Patel; S C Rao; Madhavan Krishnan Nair; Paul Bhar; Neil Desai; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2005-09-01 Impact factor: 44.544
Authors: R E Smith; A M Brown; E P Mamounas; S J Anderson; B C Lembersky; J H Atkins; H R Shibata; L Baez; P A DeFusco; E Davila; S J Tipping; J D Bearden; M P Thirlwell Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544
Authors: M Ranson; N Davidson; M Nicolson; S Falk; J Carmichael; P Lopez; H Anderson; N Gustafson; A Jeynes; G Gallant; T Washington; N Thatcher Journal: J Natl Cancer Inst Date: 2000-07-05 Impact factor: 13.506
Authors: K Roszkowski; A Pluzanska; M Krzakowski; A P Smith; E Saigi; U Aasebo; A Parisi; N Pham Tran; R Olivares; J Berille Journal: Lung Cancer Date: 2000-03 Impact factor: 5.705
Authors: E A Eisenhauer; W W ten Bokkel Huinink; K D Swenerton; L Gianni; J Myles; M E van der Burg; I Kerr; J B Vermorken; K Buser; N Colombo Journal: J Clin Oncol Date: 1994-12 Impact factor: 44.544
Authors: Liziane O F Monteiro; Renata S Fernandes; Caroline M R Oda; Sávia C Lopes; Danyelle M Townsend; Valbert N Cardoso; Mônica C Oliveira; Elaine A Leite; Domenico Rubello; André L B de Barros Journal: Biomed Pharmacother Date: 2017-11-06 Impact factor: 6.529
Authors: M C Pietanza; Matthew D Hellmann; John J Fiore; Stephanie Smith-Marrone; Ethan M Basch; Lawrence H Schwartz; Michelle S Ginsberg; Marwan Shouery; Samantha K Newman; Mary Shaw; Lauren J Rogak; Alex E Lash; Patrick Hilden; Mark G Kris Journal: J Thorac Oncol Date: 2016-03-08 Impact factor: 15.609
Authors: Ashish Saxena; Bryan J Schneider; Paul J Christos; Lauren F Audibert; Jennifer M Cagney; Ronald J Scheff Journal: Med Oncol Date: 2016-01-09 Impact factor: 3.064
Authors: David S Alberts; John A Blessing; Lisa M Landrum; David P Warshal; Lainie P Martin; Stephen L Rose; Albert J Bonebrake; Lois M Ramondetta Journal: Gynecol Oncol Date: 2012-09-14 Impact factor: 5.482
Authors: Cristina Beiu; Calin Giurcaneanu; Alexandru Mihai Grumezescu; Alina Maria Holban; Liliana Gabriela Popa; Mara Mădălina Mihai Journal: J Clin Med Date: 2020-01-23 Impact factor: 4.241